Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

This study is testing a drug called Taitacept (telitacicept) for patients with autoimmune encephalitis — a serious brain condition where the immune system mistakenly attacks the brain — specifically the anti-NMDAR or anti-LGI1 subtypes that have not responded well to standard treatments. **You may be eligible if...** - You are 14 years or older - You have been diagnosed with autoimmune encephalitis (anti-NMDAR or anti-LGI1 type) within the past 9 months - Your symptoms include at least four of the following: behavioral or cognitive changes, speech problems, seizures, abnormal movements, reduced consciousness, or autonomic problems - Your disease has not adequately responded to first-line immunotherapy treatments **You may NOT be eligible if...** - You have a different type of autoimmune encephalitis not included in this study - You have active severe infections or other serious illnesses - You have received certain medications that would interfere with the study drug - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.